乳がん診断市場：技術別、がんタイプ別、コンポーネント別、診断タイプ別、エンドユーザー別-2025-2030年の世界予測

乳がん診断市場は、2023年に65億4,000万米ドルと評価され、2024年には70億4,000万米ドルに達すると予測され、CAGR 7.79％で成長し、2030年には110億6,000万米ドルに達すると予測されています。

乳がん診断市場は、乳がんの検出と診断に使用される技術や製品によって特徴づけられる腫瘍学の重要な構成要素です。これには、マンモグラフィ、超音波、MRI、生検、高度分子診断などが含まれます。これらの診断は疾患の早期発見に不可欠であり、患者の転帰を著しく改善します。アプリケーションは病院、診断センター、研究機関に及び、スクリーニングと診断の両方のニーズに対応しています。早期かつ正確な診断により、これらのツールは治療計画や患者管理において極めて重要な役割を果たし、ヘルスケアに大きな影響を与えます。

市場成長の原動力は、世界の乳がん罹患率の上昇、診断技術の進歩、早期発見に対する意識の高まりなど、いくつかの要因による。さらに、新興市場全体のヘルスケア政策の支援とヘルスケアインフラの改善が成長を促進します。画像診断、リキッドバイオプシー、遺伝子検査におけるAIや機械学習などの技術革新が新たな機会をもたらしています。個別化医療への投資とデジタルヘルス導入の拡大は、市場の展望をさらに拡大します。しかし、市場の限界には、高度な診断機器の高コスト、規制上のハードル、診断の信頼性と患者の信頼に影響を与える偽陽性・偽陰性のリスクなどがあります。

課題としては、地域によってヘルスケアへのアクセスにばらつきがあり、診断ツールの利用可能性や導入に影響を及ぼすこと、公的医療制度における予算の制約により新技術の導入に抵抗があることなどが挙げられます。技術革新と研究が必要な分野としては、費用対効果の高い非侵襲的診断検査の開発、より高い感度と特異性を持つ画像診断技術の強化などが挙げられます。遺伝子研究やバイオマーカー研究のさらなる進展も、大きな利益をもたらす可能性があります。新たなビジネスチャンスを活かすため、利害関係者はパートナーシップ戦略、研究開発能力の強化、ビッグデータ解析の活用による診断精度と効率の向上に注力すべきです。市場はダイナミックに進化しており、技術革新による変革が進むにつれて大きな成長の余地があります。

市場力学：急速に進化する乳がん診断市場の主要市場インサイトを公開

乳がん診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の乳がん罹患率の増加
  • 乳がん診断に対する有利な償還枠組み
  • 世界の乳がん検診プログラムの増加
• 市場抑制要因
  • 乳がん診断検査に関連する高コスト
• 市場機会
  • 乳がん診断における人工知能（AI）と機械学習（ML）の統合
  • がん診断技術における継続的な研究開発活動
• 市場の課題
  • 熟練した訓練を受けた専門家の不足

ポーターのファイブフォース：乳がん診断市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：乳がん診断市場における外部からの影響の把握

外部マクロ環境要因は、乳がん診断市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：乳がん診断市場における競合情勢の把握

乳がん診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス：乳がん診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、乳がん診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：乳がん診断市場における成功への道筋を描く

乳がん診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に乳がんの発生率が増加
    • 乳がん診断に対する有利な償還枠組み
    • 世界中で乳がん検診プログラムが増加
  • 抑制要因
    • 乳がん診断検査にかかる高額な費用
  • 機会
    • 乳がん診断における人工知能（AI）と機械学習（ML）の統合
    • がん診断技術の継続的な研究開発活動
  • 課題
    • 熟練した訓練を受けた専門家の不足
• 市場セグメンテーション分析
  • 技術：分子生物学とゲノム生物学の進歩により分子検査の普及が進む
  • がんの種類：BRCA乳がんは遺伝性乳がんとして深く関与している
  • 診断タイプ：乳がん診断の非電離イメージング技術の応用の進歩
  • エンドユーザー：診断ラボにおける乳がん診断の採用率が高い
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 乳がん診断市場：技術別

• イメージング
  • アナログマンモグラフィー
  • 乳房超音波システム
  • デジタルマンモグラフィー
  • マンモグラフィー
  • MRIスキャン
  • PET/CTスキャン
• 分子検査
• 組織生検検査

第7章 乳がん診断市場：がんの種類別

• BRCA乳がん
• EGFR変異検査乳がん
• ER & PR乳がん
• HER2乳がん

第8章 乳がん診断市場：コンポーネント別

• 消耗品
  • 抗体
  • キットと試薬
  • プローブ
• 機器
  • 生検器具
  • 画像機器
  • 病理学に基づく機器

第9章 乳がん診断市場診断タイプ別

• イオン化乳房画像技術
• 非電離イメージング技術

第10章 乳がん診断市場：エンドユーザー別

• 診断検査室
• 病院と外来手術センター
• 調査・学術機関

第11章 南北アメリカの乳がん診断市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の乳がん診断市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの乳がん診断市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ソリス・マンモグラフィー、カロライナ・ブレスト・イメージングの買収を発表
  • ジョンソン・エンド・ジョンソン・インパクト・ベンチャーズ、ラテンアメリカの乳がん患者の治療アクセス向上を目指してマモテストに投資
  • シスメックス欧州は、セルカバイオテックとの欧州販売契約を通じて、先進的な乳がん診断検査MammaTyperを販売します。
• 戦略分析と提言

企業一覧

• 4D Path Inc.
• Abbott Laboratories
• Agilent Technologies, Inc.
• AstraZeneca PLC
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Biocept, Inc.
• Biodesix
• Cardinal Health
• Danaher Corporation
• Epigenomics AG
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fluxion Biosciences Inc. by Cell Microsystems
• FUJIFILM Holdings Corporation
• General Electric Company
• Hologic, Inc.
• Illumina, Inc.
• Koninklijke Philips N.V.
• NanoString Technologies, Inc.
• NeoGenomics Laboratories
• Olea Medical
• OncoGenomX
• Paragon Biosciences LLC by Catalent, Inc.
• Provista Diagnostics, Inc. by Todos Medical
• Quest Diagnostics Incorporated
• Siemens Healthcare Private Limited
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. BREAST CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. BREAST CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. BREAST CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. BREAST CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BREAST CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BREAST CANCER DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANALOG MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BREAST ULTRASOUND SYSTEM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PET/CT SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY EGFR MUTATION TEST BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER & PR BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER 2 BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PROBES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY-BASED INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NON-IONIZING IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY SURGERY CENTER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 67. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 68. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 69. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 70. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 71. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 72. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 107. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 109. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 110. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 111. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 112. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 113. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 114. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 115. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 117. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 118. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 119. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 120. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 121. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 122. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 123. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 126. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 127. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 128. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 129. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 130. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 131. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 134. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 135. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 136. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 137. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 138. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 139. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 141. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 142. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 143. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 144. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 145. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 146. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 147. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 149. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 150. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 151. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 152. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 153. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 154. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 155. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 157. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 158. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 160. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 161. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 162. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 173. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 174. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 175. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 176. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 177. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 178. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 181. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 182. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 183. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 184. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 185. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 186. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 187. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 189. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 190. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 191. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 192. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 193. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 194. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 195. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 205. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 206. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 207. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 208. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 209. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 210. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 211. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 212. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 214. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 215. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 216. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 217. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 218. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 219. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 220. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 222. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 223. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 224. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 225. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 226. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 227. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 228. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 229. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 230. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 231. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 232. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 233. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 234. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 235. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 236. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 238. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 239. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 240. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 241. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 242. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 243. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 244. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 245. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 246. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 247. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 248. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 249. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 250. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 251. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 252. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 253. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 254. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 255. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 256. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 257. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 258. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 259. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 260. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 261. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 262. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 263. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 264. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 265. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 266. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 267. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 268. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 269. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 270. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 271. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 272. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 273. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 274. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 275. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 276. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 277. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 278. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 279. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 280. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 281. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 282. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 283. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 284. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 285. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 286. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 287. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 288. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 289. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 290. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 291. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 292. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 293. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 294. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 295. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 296. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 297. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 298. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 299. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 300. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 301. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 302. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 303. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 304. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 305. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 306. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 307. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 308. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 310. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 311. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 312. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 313. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 314. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 316. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 317. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 318. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 319. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 320. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 321. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 322. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 323. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 324. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 325. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 326. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
• TABLE 327. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 328. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 329. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 330. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 331. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
• TABLE 332. SPAI

The Breast Cancer Diagnostics Market was valued at USD 6.54 billion in 2023, expected to reach USD 7.04 billion in 2024, and is projected to grow at a CAGR of 7.79%, to USD 11.06 billion by 2030.

The Breast Cancer Diagnostics market is a critical component of oncology, characterized by techniques and products used for the detection and diagnosis of breast cancer. This includes mammography, ultrasound, MRI, biopsy, and advanced molecular diagnostics. These diagnostics are essential for early disease detection, improving patient outcomes significantly. The application spans hospitals, diagnostic centers, and research institutes, addressing both screening and diagnostic needs. Through early and accurate diagnosis, these tools play a pivotal role in treatment planning and patient management, thereby carrying significant healthcare implications.

Market growth is driven by several factors, including the rising prevalence of breast cancer globally, advancements in diagnostic technology, and increased awareness about early detection. Additionally, supportive healthcare policies and improving healthcare infrastructure across emerging markets foster growth. Technological innovations such as AI and machine learning in imaging, liquid biopsies, and genetic testing are presenting new opportunities. Investments in personalized medicine and growing adoption of digital health further expand market prospects. However, market limitations include high costs of advanced diagnostic devices, regulatory hurdles, and the risk of false positives and negatives, which can affect diagnostic credibility and patient trust.

Challenging factors include the variability in healthcare access across regions, influencing the availability and adoption of diagnostic tools, and potential resistance to adopting new technologies due to budget constraints in public healthcare systems. Areas ripe for innovation and research include the development of cost-effective, non-invasive diagnostic tests, and enhanced imaging techniques with higher sensitivity and specificity. Further exploration into genetic and biomarker research could also yield substantial benefits. To capitalize on emerging opportunities, stakeholders should focus on partnership strategies, enhancing R&D capabilities, and leveraging big data analytics to improve diagnostic accuracy and efficiency. The market is dynamic and evolving, with substantial room for growth as innovations continue to transform breast cancer diagnostics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Diagnostics Market

The Breast Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of breast cancer globally
  • Favorable reimbursement framework for breast cancer diagnosis
  • Growing number of breast cancer screening programs worldwide
• Market Restraints
  • High cost associated with breast cancer diagnostic tests
• Market Opportunities
  • Integration of artificial intelligence (AI) and machine learning (ML) in breast cancer diagnostic
  • Ongoing research and development activities in cancer diagnostic techniques
• Market Challenges
  • Dearth of the skilled and trained professionals

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Diagnostics Market

A detailed market share analysis in the Breast Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Diagnostics Market

A strategic analysis of the Breast Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 4D Path Inc., Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Cardinal Health, Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc. by Cell Microsystems, FUJIFILM Holdings Corporation, General Electric Company, Hologic, Inc., Illumina, Inc., Koninklijke Philips N.V., NanoString Technologies, Inc., NeoGenomics Laboratories, Olea Medical, OncoGenomX, Paragon Biosciences LLC by Catalent, Inc., Provista Diagnostics, Inc. by Todos Medical, Quest Diagnostics Incorporated, Siemens Healthcare Private Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technique, market is studied across Imaging, Molecular Testing, and Tissue Biopsy Tests. The Imaging is further studied across Analog Mammography, Breast Ultrasound System, Digital Mammography, Mammography, MRI Scan, and PET/CT Scan.
• Based on Cancer Type, market is studied across BRCA Breast Cancer, EGFR Mutation Test Breast Cancer, ER & PR Breast Cancer, and HER 2 Breast Cancer.
• Based on Component, market is studied across Consumables and Instruments. The Consumables is further studied across Antibodies, Kits & Reagents, and Probes. The Instruments is further studied across Biopsy Instruments, Imaging Instruments, and Pathology-Based Instruments.
• Based on Diagnostic Type, market is studied across Ionizing Breast Imaging Technologies and Non-Ionizing Imaging Technologies.
• Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Ambulatory Surgery Center, and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of breast cancer globally
    • 5.1.1.2. Favorable reimbursement framework for breast cancer diagnosis
    • 5.1.1.3. Growing number of breast cancer screening programs worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with breast cancer diagnostic tests
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of artificial intelligence (AI) and machine learning (ML) in breast cancer diagnostic
    • 5.1.3.2. Ongoing research and development activities in cancer diagnostic techniques
  • 5.1.4. Challenges
    • 5.1.4.1. Dearth of the skilled and trained professionals
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technique: Advancements in molecular and genomic biology advancing the penetration of molecular testing
  • 5.2.2. Cancer Type: BRCA breast cancer is highly implicated as a hereditary breast cancer
  • 5.2.3. Diagnostic Type: Advancing applications of non-ionizing imaging technologies for breast cancer diagnostics
  • 5.2.4. End-User: High adoption of breast cancer diagnostics in the diagnostic laboratories
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Breast Cancer Diagnostics Market, by Technique

• 6.1. Introduction
• 6.2. Imaging
  • 6.2.1. Analog Mammography
  • 6.2.2. Breast Ultrasound System
  • 6.2.3. Digital Mammography
  • 6.2.4. Mammography
  • 6.2.5. MRI Scan
  • 6.2.6. PET/CT Scan
• 6.3. Molecular Testing
• 6.4. Tissue Biopsy Tests

7. Breast Cancer Diagnostics Market, by Cancer Type

• 7.1. Introduction
• 7.2. BRCA Breast Cancer
• 7.3. EGFR Mutation Test Breast Cancer
• 7.4. ER & PR Breast Cancer
• 7.5. HER 2 Breast Cancer

8. Breast Cancer Diagnostics Market, by Component

• 8.1. Introduction
• 8.2. Consumables
  • 8.2.1. Antibodies
  • 8.2.2. Kits & Reagents
  • 8.2.3. Probes
• 8.3. Instruments
  • 8.3.1. Biopsy Instruments
  • 8.3.2. Imaging Instruments
  • 8.3.3. Pathology-Based Instruments

9. Breast Cancer Diagnostics Market, by Diagnostic Type

• 9.1. Introduction
• 9.2. Ionizing Breast Imaging Technologies
• 9.3. Non-Ionizing Imaging Technologies

10. Breast Cancer Diagnostics Market, by End-User

• 10.1. Introduction
• 10.2. Diagnostic Laboratories
• 10.3. Hospitals & Ambulatory Surgery Center
• 10.4. Research & Academic Institutes

11. Americas Breast Cancer Diagnostics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Breast Cancer Diagnostics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Breast Cancer Diagnostics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Solis Mammography Announces Acquisition of Carolina Breast Imaging
  • 14.3.2. Johnson & Johnson Impact Ventures Invests in Mamotest to Improve Access to Care for Breast Cancer Patients in Latin America
  • 14.3.3. Sysmex Europe Distributes MammaTyper, an Advanced Breast Cancer Diagnostic Assay, Through The European Distribution Agreement With Cerca Biotech
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 4D Path Inc.
• 2. Abbott Laboratories
• 3. Agilent Technologies, Inc.
• 4. AstraZeneca PLC
• 5. Becton, Dickinson and Company
• 6. Bio-Rad Laboratories, Inc.
• 7. Biocept, Inc.
• 8. Biodesix
• 9. Cardinal Health
• 10. Danaher Corporation
• 11. Epigenomics AG
• 12. Exact Sciences Corporation
• 13. F. Hoffmann-La Roche Ltd.
• 14. Fluxion Biosciences Inc. by Cell Microsystems
• 15. FUJIFILM Holdings Corporation
• 16. General Electric Company
• 17. Hologic, Inc.
• 18. Illumina, Inc.
• 19. Koninklijke Philips N.V.
• 20. NanoString Technologies, Inc.
• 21. NeoGenomics Laboratories
• 22. Olea Medical
• 23. OncoGenomX
• 24. Paragon Biosciences LLC by Catalent, Inc.
• 25. Provista Diagnostics, Inc. by Todos Medical
• 26. Quest Diagnostics Incorporated
• 27. Siemens Healthcare Private Limited
• 28. Thermo Fisher Scientific Inc.